



Centre for  
Public Health

# **Merseyside Inter Agency Drug Misuse Database**

January - March 2010

**St Helens DAT**

Quarter 4 2009/10

**Lloyd Baron, Steven Griffith,  
Martin Chandler, Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

#### Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Ellie McCoy and Paul Duffy.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

#### Contacts:

Martin Chandler  
IAD Manager  
Centre for Public Health  
Faculty of Health & Applied Social Sciences  
Liverpool John Moores University  
4th Floor, Kingsway House  
Hatton Gardens  
Liverpool  
L3 2AY

(0151) 904 6031

[m.chandler@ljmu.ac.uk](mailto:m.chandler@ljmu.ac.uk)

Lloyd Baron  
IAD Researcher

(0151) 231 8014

[L.R.Baron@ljmu.ac.uk](mailto:L.R.Baron@ljmu.ac.uk)

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

## Contents

	<b><u>Page</u></b>
<b>Introduction</b>	<b>1</b>
<b>Arrest Referral</b>	<b>3</b>
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
<b>Needle and Syringe Programmes (NSPs)</b>	<b>5</b>
<b>Agency</b>	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency NSP Clients, by Gender	
Table 13: Main Drug of Use for All Agency NSP Clients, by Gender	
Table 14: Main Drug of Use, for New Agency NSP Clients, by Age Group	
<b>Pharmacy</b>	<b>11</b>
Table 15: Individuals by Gender	
Table 16: Individuals by Age Group	
Table 17: Year to Date, by Gender & Age Group	
<b>Combined</b>	<b>12</b>
Table 18: Individuals in NSP, by Gender	
Table 19: Individuals in NSP, by Gender: Steroid Users omitted	
Table 20: Individuals in NSP, by Age Group	
Table 21: Individuals in NSP, by Age Group: Steroid Users omitted	
Table 22: Year to Date, by Gender & Age Group	
Table 23: Total Syringes Provided	

## **National Drug Treatment Monitoring System (NDTMS) 14**

Table 24: Individuals in contact with Treatment Services, by Gender

Table 25: Year to Date, by Gender

Table 26: Individuals in contact with Treatment Services, by Age Group

Table 27: Year to Date, by Age Group

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Table 29: Individuals in contact with Treatment Services, by Main Drug of Use

## **Connexions 17**

Table 30: Individuals in Contact with Connexions, by Gender

Table 31: Year to Date, by Gender

Table 32: Individuals in Contact with Connexions, by Age

Table 33: Year to Date, by Age

Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 35: Year to Date, by Drug/Alcohol Problem

## **Combined Datasets 19**

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 37: Year to Date, by Gender & Age Group

## **Cross Matched Datasets 20**

Fig 1: Crossover between Agency NSP and NDTMS datasets

Fig 2: Crossover between Pharmacy NSP and NDTMS datasets

Fig 3: Crossover between YTD Agency NSP and NDTMS datasets

Fig 4: Crossover between YTD Pharmacy NSP and NDTMS datasets

## Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

**ARREST REFERRAL (AR)****Quarter 4 (2009/10)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

**Table 1: Individuals assessed, by Gender & Age Group**

Gender	n	%
Male	52	88.1
Female	7	11.9
Age Group		
Under 18	0	0.0
18-19	2	3.4
20-24	10	16.9
25-29	13	22.0
30-34	13	22.0
35-39	12	20.3
40-44	6	10.2
45+	3	5.1
<b>Total</b>	59	100

**Table 2: Year to Date, by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	15	5.3	2	4.5	17	5.2
20-24	64	22.8	11	25.0	75	23.1
25-29	58	20.6	8	18.2	66	20.3
30-34	60	21.4	11	25.0	71	21.8
35-39	47	16.7	4	9.1	51	15.7
40-44	20	7.1	3	6.8	23	7.1
45+	17	6.0	5	11.4	22	6.8
<b>Total</b>	281	100	44	100	325	100

**Table 3: Reported Main Drug(s) of Use, by Frequency of Use**

Drug of Use	Daily	Weekly	Monthly
Amphetamines	-	-	-
Benzodiazepines	-	-	-
Cannabis	3	0	0
Crack	0	0	1
Cocaine	2	4	28
Ecstasy	-	-	-
Heroin	11	6	1
Methadone	-	-	-
Other	-	-	-

**2 individuals did not report their main drug of use**

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.



## NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2009/10)

### Introduction

Data are collected directly from NSP providers. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

Please note that the closure of the Lighthouse Project (LHP) resulted in a severe, but temporary, disruption to the agency-based needle and syringe programme service. Consequently there is a short period within Quarter 2 (2009/10) for which we have no data this is reflected in the year to date figures supplied for this quarter. All sites have since reopened and are supplying monitoring data however the year to date figures may appear lower comparable to Q4 (2008/09) due to LHP closure. Please contact us if you require further information.

### AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	96	91.4
Female	9	8.6
<i>Total</i>	105	100
All Clients		
Male	314	88.5
Female	41	11.5
<i>Total</i>	355	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	19	70.4
Female	8	29.6
<i>Total</i>	27	100
All Clients		
Male	161	80.9
Female	38	19.1
<i>Total</i>	199	100

**Table 6: Individuals by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	10	9.5	12	3.4
20-24	35	33.3	62	17.5
25-29	23	21.9	66	18.6
30-34	12	11.4	56	15.8
35-39	15	14.3	72	20.3
40-44	7	6.7	55	15.5
45+	3	2.9	32	9.0
<b>Total</b>	105	100	355	100

**Table 7: Individuals by Age Group: Steroid Users omitted**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	7.4	2	1.0
20-24	4	14.8	9	4.5
25-29	3	11.1	21	10.6
30-34	5	18.5	38	19.1
35-39	6	22.2	55	27.6
40-44	5	18.5	47	23.6
45+	2	7.4	27	13.6
<b>Total</b>	27	100	199	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	11	3.5	1	2.4
20-24	57	18.2	5	12.2
25-29	57	18.2	9	22.0
30-34	48	15.3	8	19.5
35-39	65	20.7	7	17.1
40-44	49	15.6	6	14.6
45+	27	8.6	5	12.2
<b>Total</b>	314	100	41	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	<1	1	2.6
20-24	5	3.1	4	10.5
25-29	13	8.1	8	21.1
30-34	30	18.6	8	21.1
35-39	49	30.4	6	15.8
40-44	41	25.5	6	15.8
45+	22	13.7	5	13.2
<b>Total</b>	161	100	38	100

Table 10: Year to Date, by Gender &amp; Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	6	<1	0	0.0	6	<1
18-19	43	5.7	3	3.8	46	5.5
20-24	137	18.2	10	12.8	147	17.7
25-29	159	21.1	15	19.2	174	20.9
30-34	128	17.0	14	17.9	142	17.1
35-39	139	18.4	17	21.8	156	18.8
40-44	86	11.4	11	14.1	97	11.7
45+	56	7.4	8	10.3	64	7.7
<b>Total</b>	754	100	78	100	832	100

Table 11: Year to Date, by Gender &amp; Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	<1	0	0.0	1	<1
18-19	2	<1	3	4.1	5	1.3
20-24	19	5.8	9	12.2	28	7.0
25-29	37	11.3	14	18.9	51	12.8
30-34	67	20.6	14	18.9	81	20.3
35-39	91	27.9	15	20.3	106	26.5
40-44	62	19.0	11	14.9	73	18.3
45+	47	14.4	8	10.8	55	13.8
<b>Total</b>	326	100	74	100	400	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	1	1.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	7	7.3	5	55.6
Methadone	2	2.1	0	0.0
Steroids	77	80.2	1	11.1
Cyclizine	0	0.0	0	0.0
Unknown	9	9.4	3	33.3
<b>Total</b>	96	100	9	100

Table 13: Main Drug of Use for All Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	14	4.5	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	102	32.5	26	63.4
Cyclizine	3	1.0	1	2.4
Morphine	0	0.0	0	0.0
Methadone	25	8.0	7	17.1
Steroids	153	48.7	3	7.3
Unknown	17	5.4	4	9.7
<b>Total</b>	314	100	41	100

**Current Quarter; Melanotan Clients**

- 3 New Male clients reported using melanotan during Q4
- 4 New Female clients reported using melanotan during Q4
- 7 Male clients reported using melanotan during Q4
- 6 Female clients reported using melanotan during Q4

Table 14: Main Drug of Use for New Agency NSP Clients, by Age Group

Age Group	Ampheta- mine		Benzodi- azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0.0	-	-	-	-	-	-	0	0.0	0	0.0	0	0.0
18-19	0	0.0	-	-	-	-	-	-	0	0.0	0	0.0	8	10.3
20-24	0	0.0	-	-	-	-	-	-	0	0.0	0	0.0	31	39.7
25-29	0	0.0	-	-	-	-	-	-	2	16.7	0	0.0	20	25.6
30-34	0	0.0	-	-	-	-	-	-	2	16.7	2	100	7	9.0
35-39	0	0.0	-	-	-	-	-	-	5	41.7	0	0.0	9	11.5
40-44	1	100	-	-	-	-	-	-	3	25.0	0	0.0	2	2.6
45+	0	0.0	-	-	-	-	-	-	0	0.0	0	0.0	1	1.3
<b>Total</b>	1	100	-	-	-	-	-	-	12	100	2	100	78	100

% Totals are by Drug, not Age Group.

**Please Note:** Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

## PHARMACY NSP

Table 15: Individuals by Gender

New Clients	n	%
Male	178	89.4
Female	21	10.6
<i>Total</i>	199	100
All Clients		
Male	351	87.5
Female	50	12.5
<i>Total</i>	401	100

Table 16: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	1.0	2	<1
18-19	6	3.0	9	2.2
20-24	12	6.0	21	5.2
25-29	31	15.6	60	15.0
30-34	39	19.6	98	24.4
35-39	47	23.6	105	26.2
40-44	44	22.1	73	18.2
45+	18	9.0	33	8.2
<i>Total</i>	199	100	401	100

Table 17: Year to Date, by Gender &amp; Age Group

Age Group	Gender				<i>Total in Age Group</i>	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	<1	0	0.0	3	<1
18-19	12	1.4	1	<1	13	1.3
20-24	52	6.1	11	8.9	63	6.5
25-29	126	14.8	33	26.6	159	16.3
30-34	191	22.5	33	26.6	224	23.0
35-39	245	28.9	32	25.8	277	28.5
40-44	138	16.3	9	7.3	147	15.1
45+	82	9.7	5	4.0	87	8.9
<i>Total</i>	849	100	124	100	973	100

## COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

**Table 18: Individuals in NSP, by Gender**

New Clients	n	%
Male	263	90.1
Female	29	9.9
<i>Total</i>	292	100
All Clients		
Male	595	88.3
Female	79	11.7
<i>Total</i>	674	100

**Table 19: Individuals in NSP, by Gender: Steroid Users Omitted\***

New Clients	n	%
Male	186	86.9
Female	28	13.1
<i>Total</i>	214	100
All Clients		
Male	442	85.3
Female	76	14.7
<i>Total</i>	518	100

\*Only known steroid users, based on Agency NSP data, have been omitted.

**Table 20: Individuals in NSP, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	<1	2	<1
18-19	15	5.1	20	3.0
20-24	44	15.1	78	11.6
25-29	52	17.8	115	17.1
30-34	51	17.5	132	19.6
35-39	60	20.5	153	22.7
40-44	48	16.4	114	16.9
45+	20	6.8	60	8.9
<i>Total</i>	292	100	674	100



**Table 21: Individuals in NSP by Age Group: Steroid Users Omitted**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	<1	2	<1
18-19	7	3.3	10	1.9
20-24	13	6.1	25	4.8
25-29	32	15.0	70	13.5
30-34	44	20.6	114	22.0
35-39	51	23.8	136	26.3
40-44	46	21.5	106	20.5
45+	19	8.9	55	10.6
<b>Total</b>	214	100	518	100

**Table 22: Year to Date, by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	9	<1	0	0.0	9	<1
18-19	53	3.7	4	2.2	57	3.5
20-24	181	12.5	17	9.6	198	12.2
25-29	254	17.5	41	23.0	295	18.1
30-34	286	19.7	40	22.5	326	20.0
35-39	338	23.3	45	25.3	383	23.5
40-44	199	13.7	19	10.7	218	13.4
45+	129	8.9	12	6.7	141	8.7
<b>Total</b>	1,449	100	178	100	1,627	100

**Table 23: Total Syringes Provided**

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	17,104	6,289	23,393	97,227

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

## National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2009/10)

### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

### New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

**Table 24: Individuals in Contact with Treatment Services, by Gender**

<b>New Clients</b>	n	%
Male	80	86.0
Female	13	14.0
<i>Total</i>	93	100
<b>All Clients</b>		
Male	895	76.3
Female	278	23.7
<i>Total</i>	1,173	100

**Table 25: Year to Date, by Gender**

<b>New Clients</b>	n	%
Male	329	77.4
Female	96	22.6
<i>Total</i>	425	100
<b>All Clients</b>		
Male	903	76.3
Female	280	23.7
<i>Total</i>	1,183	100

**Table 26: Individuals in Contact with Treatment Services, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	6	6.5	118	10.1
18-19	0	0.0	17	1.4
20-24	12	12.9	127	10.8
25-29	11	11.8	215	18.3
30-34	16	17.2	251	21.4
35-39	23	24.7	220	18.8
40-44	16	17.2	130	11.1
45+	9	9.7	95	8.1
<b>Total</b>	93	100	1,173	100

**Table 27: Year to Date, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	38	8.9	120	10.1
18-19	6	1.4	17	1.4
20-24	47	11.1	129	10.9
25-29	67	15.8	220	18.6
30-34	92	21.6	252	21.3
35-39	85	20.0	220	18.6
40-44	59	13.9	133	11.2
45+	31	7.3	92	7.8
<b>Total</b>	425	100	1,183	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	91	97.8	1,150	98.0
White Irish	0	0.0	4	<1
Other White	0	0.0	2	<1
White & Black Caribbean	0	0.0	3	<1
White & Black African	0	0.0	2	<1
African	0	0.0	1	<1
White & Asian	0	0.0	1	<1
Other Mixed	1	1.10	1	<1
Other Asian	0	0.0	2	<1
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	3	<1
Other Black	0	0.0	2	<1
Unknown	1	1.1	2	<1
<b>Total</b>	93	100	1,173	100

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	66	71.0	746	63.6
Methadone	4	4.3	74	6.3
Other Opiates	2	2.2	33	2.8
Benzodiazepine	0	0.0	6	<1
Amphetamines	5	5.4	28	2.4
Cocaine	3	3.2	96	8.2
Crack	1	1.1	18	1.5
Ecstasy	0	0.0	2	<1
Hallucinogens	0	0.0	1	<1
Cannabis	12	12.9	150	12.8
Solvents	0	0.0	4	<1
Prescription Drugs	0	0.0	12	1.0
Other/Unknown	0	0.0	3	<1
<b>Total</b>	93	100	1,173	100

## CONNEXIONS

### Quarter 4 (2009/10)

#### Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

**Table 30: Individuals in Contact with Connexions, by Gender**

Gender	n	%
Male	29	54.7
Female	24	45.3
<b>Total</b>	53	100

**Table 31: Year to Date, by Gender**

Gender	n	%
Male	47	56.0
Female	37	44.0
<b>Total</b>	84	100

**Table 32: Individuals in Contact with Connexions, by Age**

Age Group	n	%
16	13	24.5
17	20	37.7
18	11	20.8
19	9	17.0
<b>Total</b>	53	100

**Table 33: Year to Date, by Age**

Age Group	n	%
16	24	28.6
17	21	25.0
18	22	26.2
19	17	20.2
<b>Total</b>	84	100

**Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem**

Substance	n	%
Alcohol/Other*	17	32.1
Drugs	36	67.9
<b>Total</b>	53	100

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

**Table 35: Year to Date, by Drug/Alcohol problem**

Substance	n	%
Alcohol/Other*	24	28.6
Drugs	60	71.4
<b>Total</b>	84	100

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

## COMBINED DATASETS

Quarter 4 (2009/10)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSP (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

**Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group**

Gender	n	%
Male	1,392	79.9
Female	350	20.1
Age Group		
Under 18	144	8.3
18-19	55	3.2
20-24	203	11.7
25-29	316	18.1
30-34	346	19.9
35-39	330	18.9
40-44	211	12.1
45+	137	7.9
<b>Total</b>	1,742	100

**Table 37: Year to Date, by Gender and Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	128	5.5	34	7.3	162	5.8
18-19	93	4.0	26	5.6	119	4.3
20-24	312	13.4	63	13.5	375	13.4
25-29	419	18.0	98	21.1	517	18.5
30-34	469	20.1	90	19.4	559	20.0
35-39	459	19.7	86	18.5	545	19.5
40-44	262	11.2	41	8.8	303	10.8
45+	191	8.2	27	5.8	218	7.8
<b>Total</b>	2,333	100	465	100	2,798	100

## CROSS-MATCHED DATASETS


Quarter 4 (2009/10)

Data are shown for the crossover between each type of NSP and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.


For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of NSP site.

**Fig 1: Crossover between Agency NSP and NDTMS datasets**




**Fig 2: Crossover between Pharmacy NSP and NDTMS datasets**





**Fig 3: Year to Date Crossover between Agency NSP and NDTMS datasets**



**Fig 4: Year to Date Crossover between Pharmacy NSP and NDTMS datasets**

